Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus ZIPAN 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus ZIPAN 50.
ASTRAMORPH PF vs ZIPAN-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
ZIPAN-50 (zinc acetate) is a dietary supplement that provides zinc, an essential trace element. Zinc acts as a cofactor for numerous enzymes, including those involved in DNA synthesis, cell division, and immune function. It also stabilizes cell membranes and has antioxidant properties.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
50 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Terminal elimination half-life is 4 hours (range 3-5 hours) in patients with normal renal function; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal excretion of unchanged drug accounts for approximately 60%, with 30% as glucuronide conjugate. Biliary/fecal elimination contributes 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic